

Pfizer – Recall of Nurtec® ODT (rimegepant)

- On March 16, 2023, <u>Pfizer announced</u> a consumer-level recall of <u>Nurtec ODT</u> (<u>rimegepant</u>) 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets because the tablets are in a non-child resistant blister card.
 - For new or refill prescriptions, pharmacists will place Nurtec ODT blister packages into vials with child-resistant lids when filling patient prescriptions.
- The recalled Nurtec ODT was sold at pharmacies nationwide between December 2021 and March 2023.

Product Description	NDC#	Expiration Date
Nurtec ODT (rimegepant) 75mg 8-unit dose blister pack	72618-3000-2	All dates through 6/2026

- Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine in adults.
- Nurtec ODT packaging does not meet the child-resistant packaging requirements for oral prescription drugs, potentially posing a risk of harm if the contents are swallowed by young children.
- Patients who are currently using the recalled Nurtec ODT should continue to use Nurtec ODT as
 prescribed by their healthcare provider. Patients should store Nurtec ODT in a safe location, out of
 the reach and sight of children. Patients should contact Pfizer to request a child-resistant pouch in
 which to store the medication.
- Anyone with an existing inventory of the recalled product should place Nurtec ODT blister packages into vials with child-resistant lids when filling patient prescriptions.
- Contact Pfizer by phone at 1-800-879-3477 or by e-mail at www.Nurtec.com/PackagingUpdate or www.Nurtec.com for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.